click on circles to display study description...

Novavax PREVEND-19 phase 3 US (2019nCoV-301), 2021 NCT04611802

Nuvaxovid (NVX-CoV2373) Novavax (n=-9) vs. placebo (n=-9)

randomized controlled trial

NVX-CoV2373

placebo

COVID-19 prophylaxis (excluding children)

observer-blinded

119 locations in the United States and Mexico

Efficacy endpoints were accrued from January 25 through April 30, 2021, a time when the Alpha (B.1.1.7) variant became the predominant strain in the U.S

Novavax phase 2 South Africa (2019nCoV-501), 2021 NCT04533399

Nuvaxovid (NVX-CoV2373) Novavax (n=2199) vs. placebo (n=2188)

randomized controlled trial

NVX-CoV2373 2 doses
two doses, administered 21 days apart, of NVX-CoV2373 nanoparticle vaccine(5 μg recombinant spike protein with 50 μg Matrix-M1 adjuvant)

placebo

COVID-19 prophylaxis (excluding children)

B.1.351 (501Y.V2) variant was largely predominant during trial efficacy endpoint accrual

double-blind

South Africa

phase 2a/b